Skip to main content Skip to section navigation Skip to footer
Careers News & Media Contact
OPKO Health, Inc. OPKO Health, Inc.
  • Therapies
    • Overview
    • Ngenla
    • Rayaldee
  • Research
    • Overview
    • Pipeline
    • Publications
    • Scientific Presentations
  • Diagnostics
  • Company
    • Overview
    • Leadership
    • Locations
  • Partnerships
  • Investors
    • Overview
    • News / Events
    • Presentations
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Careers
  • News & Media
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News / Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Presentations
  • Company Info
    • Overview
    • Proxy Materials
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
    • Form 8937
  • Governance
    • Overview
    • Management Team
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News / Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
May 15, 2015 9:06am EDT

OPKO Announces Publication of Study Using Kallikrein Biomarkers of the 4Kscore® Test in a Large Community-Based Referral Cohort

May 11, 2015 4:00pm EDT

OPKO Announces First Quarter Operating and Financial Results

May 07, 2015 8:56am EDT

CORRECTING and REPLACING OPKO To Announce First Quarter Financial Results on May 11, 2015

May 05, 2015 11:07am EDT

OPKO Health Acquires EirGen Pharma

Apr 21, 2015 10:57am EDT

OPKO Announces Publication of ProtecT Study Using Kallikrein Biomarkers in 4Kscore Test

Apr 01, 2015 1:26pm EDT

Conversion Right Triggered on OPKO 3.0% Convertible Senior Notes

Mar 27, 2015 9:12am EDT

Phase 3 Data Supporting Rayaldee™ As a Treatment for Secondary Hyperparathyroidism in Chronic Kidney Disease to be Presented at NKF 2015 Spring Clinical Meetings

Mar 23, 2015 9:06am EDT

OPKO Investee SciVac Ltd. Enters into Transaction with Levon Resources

Mar 18, 2015 9:04am EDT

OPKO Lab Receives Accreditation From College of American Pathologists

Mar 06, 2015 8:30am EST

Phase 3 Data Supporting Rayaldee As a Treatment for Secondary Hyperparathyroidism in Chronic Kidney Disease to be Presented at ENDO 2015 Conference

  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 28
  • Page 29
  • Page 30
  • Page 31
  • Page 32
  • Page 33
  • Page 34
  • Page 35
  • Page 36
  • Page 37
  • …
  • Page 52
  • Next Pagearrow_forward
rss_feed News RSS
  • emailEmail Alerts
  • location_cityCompany Profile
  • contact_pageContacts
  • rss_feedRSS News Feed
  • account_treeSitemap

OPKO Health, Inc.
4400 Biscayne Boulevard
Miami, FL 33137


T: 305-575-4100
contact@opko.com

©2025 OPKO Health, Inc. All Rights Reserved.
Privacy Policy Governance Terms of use Sitemap